View a selection of recent media and panel appearances below.
Medicaid Plans Ramp Up Warnings On Pay Rates, Mismatch Post-PHE
In an October 21 article from Inside Health Policy, Smolinski offered insights on the rate and acuity mismatch – stating the pressure on Medicaid costs resulting from the acuity shift is not surprising — but perhaps the magnitude is. She also points out Medicaid plans have highlighted states’ obligation to provide actuarially sound rates.
May 24, 2023
Smolinski was interviewed about the CMS proposal for a Medicaid drug price name and shame policy. CMS has proposed a new Medicaid rule aimed at increasing transparency around some drug prices and PBM practices. Under the proposal, Medicaid would not be given power over drug prices. Rather, it would create what Capitol Street consultants call a “Medicaid Rx wall of shame” on which it would post the prices of three to 10 drugs Medicaid believes have abnormally high prices or have been subject to large price increases.
JP Morgan keynote discussion with FDA Commissioner Califf and ARPA-H Director Wegrzyn
January 10, 2023
For the Jan. 10 lunchtime keynote at the JP Morgan Healthcare Conference, Ipsita Smolinski of Capitol Street and Rachel Vatnsdal of JP Morgan co-host a discussion with FDA Commissioner Robert Califf and ARPA-H Director Renee Wegrzyn about the Biden Administration’s 2023 priorities for Life Sciences, BioPharma and MedTech.
Planning for Fiscal Strength in Changing Times
During a June 23 virtual event presented by Allscripts and Modern Healthcare Custom Media, Ipsita Smolinski, Managing Partner of Capitol Street Research and Senior Strategic Adviser at McAllister & Quinn, and Richard Mulry, President and CEO of Northwell Holdings and Ventures, offered insights into and guidance specific to where hospital systems should be prioritizing as they do strategic planning, during a COVID time of health equity and physician employment along with increasing transparency rules for health systems, looking ahead to the next several years.
